Back to BAKER BROS. ADVISORS LP BAKER BROS. ADVISORS LP

AKROAKRO
Showing 6 of 22 quarters

Position history for BAKER BROS. ADVISORS LPBAKER BROS. ADVISORS LP's holdings in AKERO THERAPEUTICS INC

As of its Q3 2025 13F, Baker Bros. Advisors held 324,630 shares of AKRO (Akero Therapeutics), worth $15.4M. Baker Bros. Advisors' 13F filings listed AKRO from Q3 2020 to Q3 2025, 21 quarterly filings. AKRO was 0.1% of Baker Bros. Advisors' reported 13F portfolio.

Final Value

$0

Final Shares

0

Total Value Change

-$31.5M

Total Shares Change

-1.1M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q4
Latest
Exited
0
-100.0%
$00.0%$47.62
0
2025-Q3
Unchanged
324,630
0.0%
$15.4M0.1%$47.62
0
2025-Q2
Decreased
324,630
-40.8%
$17.3M0.2%$56.19
0
2025-Q1
Decreased
548,713
-50.0%
$22.2M0.2%$42.72
0
2024-Q4
Unchanged
1.1M
0.0%
$30.5M0.3%$27.96
0
2024-Q3
Unchanged
1.1M
0.0%
$31.5M0.3%$28.24
0

Other major holders of AKRO: Janus Henderson Group Ltd., BlackRock, Inc., RTW INVESTMENTS, LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used